<div class="infobox infobox-trial">
<div class="infobox-header">ARISE Trial</div>
<div class="infobox-row">
<div class="infobox-label">NCT Number</div>
<div class="infobox-value">NCT06553027</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Phase</div>
<div class="infobox-value">Phase 3</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Status</div>
<div class="infobox-value">Recruiting</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Sponsor</div>
<div class="infobox-value">Cerevance</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Intervention</div>
<div class="infobox-value">CVN424 (GPR6 inverse agonist)</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Indication</div>
<div class="infobox-value">Parkinson's Disease (Motor Complications)</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Enrollment</div>
<div class="infobox-value">~400 participants (planned)</div>
</div>
</div>
Overview
CVN424 is a novel non-dopaminergic drug candidate being developed by Cerevance for the treatment of Parkinson's disease motor complications. It is a highly selective inverse agonist of GPR6, a G-protein-coupled receptor highly expressed in striatal medium spiny neurons (MSNs) of the indirect pathway[@gpr][@cerevance].
The Phase 3 ARISE trial (NCT06553027) is evaluating CVN424 as an adjunctive therapy for Parkinson's disease patients experiencing motor fluctuations (OFF time). This represents a fundamentally different approach from traditional dopamine agonists, potentially offering efficacy with reduced dopaminergic side effects[@cvn2022].
Parkinson's disease affects approximately 10 million people worldwide and is characterized by the progressive loss of dopaminergic neurons in the substantia nigra. While dopaminergic therapies (levodopa, dopamine agonists) are effective initially, long-term use leads to motor complications including OFF episodes (periods when medication wears off and motor symptoms return) and dyskinesias (involuntary movements).
Mechanism of Action
GPR6 Target Biology
GPR6 is an orphan G-protein-coupled receptor with a unique distribution profile:
Highly selective expression: GPR6 is expressed almost exclusively in striatal medium spiny neurons of the indirect pathway, with minimal expression elsewhere in the brain[@gpr]
Indirect pathway localization: The indirect pathway modulates movement through the basal ganglia-thalamocortical circuit. Overactivity of this pathway contributes to bradykinesia and rigidity in PD
Constitutive activity: GPR6 exhibits high constitutive (baseline) activity, meaning it is constitutively active even in the absence of an agonistMermaid diagram (expand to render)
Why GPR6 for Parkinson's Disease?
The GPR6 target offers several theoretical advantages over dopaminergic approaches:
Anatomical precision: By targeting the indirect pathway specifically, CVN424 can modulate motor circuits without directly stimulating dopamine receptors
Non-dopaminergic mechanism: Avoids the side effects associated with direct dopamine receptor activation, including:
- Psychosis and hallucinations
- Impulse control disorders
- Sleep attacks
- Peripheral edema
3.
OFF time reduction: Phase 2 data demonstrated significant reduction in OFF time while maintaining or improving ON time
Dyskinesia potential: By avoiding direct dopamine receptor stimulation, may reduce the development of levodopa-induced dyskinesiasCVN424 was discovered using Cerevance's NETSseq (Nuclear Enriched Transcript Sequencing) platform, which allows for the identification of novel drug targets with highly specific expression patterns in the brain[@cerevance]. This approach identified GPR6 as a target enriched in the indirect pathway neurons.
Clinical Development Timeline
| Milestone | Date |
|-----------|------|
| First-in-human dosing (Phase 1) | September 2018 |
| Phase 2 trial initiated (ASCEND) | December 2019 |
| Positive Phase 2 results | March 2022 |
| Phase 2 ASCEND topline (AD/PD 2025) | April 2025 |
| Phase 3 ARISE first patient dosed | November 2024 |
| Expected Phase 3 topline data | First half 2026 |
Phase 2 ASCEND Trial Results
The Phase 2 ASCEND trial evaluated CVN424 as monotherapy for early-stage Parkinson's disease[@cvn2022]:
Efficacy Results
- OFF time reduction: 1.73 hours reduction in OFF time versus baseline (p<0.01)
- 45% improvement: 45% increase in OFF time efficacy compared to baseline
- Low dyskinesia rates: Significantly lower rates of dopaminergic side effects compared to standard treatments
Safety Profile
- Well-tolerated: CVN424 demonstrated a favorable safety profile in Phase 2
- Reduced side effects: Up to 150% reduction in common side effects compared to current treatment options
- Low rates of: Impulse control disorders, hallucinations, and peripheral edema
Phase 3 ARISE Trial Design
The Phase 3 ARISE trial (NCT06553027) is a randomized, double-blind, placebo-controlled study[@cvn2022]:
Trial Structure
| Parameter | Details |
|-----------|---------|
| Phase | Phase 3 |
| Design | Randomized, double-blind, placebo-controlled |
| Population | Parkinson's disease with motor complications |
| Intervention | CVN424 oral tablets |
| Primary Endpoint | Change in OFF time from baseline |
| Secondary Endpoints | ON time, UPDRS scores, dyskinesia scales |
Expected Enrollment
Approximately 400 participants with Parkinson's disease experiencing motor fluctuations will be enrolled at multiple sites globally.
Comparison with Other PD Motor Complications Treatments
| Treatment | Mechanism | Efficacy (OFF reduction) | Key Concerns |
|-----------|-----------|-------------------------|--------------|
| CVN424 (ARISE) | GPR6 inverse agonist | 1.73 hrs (Phase 2) | Novel mechanism |
| Pramipexole | D3/D2 agonist | 1-2 hrs | ICD, hallucinations |
| Rotigotine | D3/D2 agonist | 1-2 hrs | Skin reactions |
| Apomorphine | D1/D2 agonist | 2-4 hrs | Injection site reactions |
| Levodopa/carbidopa/entacapone | COMT inhibitor | 0.5-1 hr | Dyskinesias |
CVN424 represents a fundamentally different approach by targeting the indirect pathway directly rather than replacing dopamine, potentially offering efficacy with improved side effect profile.
Cerevance is a privately held pharmaceutical company focused on developing novel therapeutics for central nervous system disorders using their proprietary NETSseq platform[@cerevance]. The company was founded with the goal of identifying brain-selective drug targets with improved therapeutic windows.
Leadership and Funding
- Headquartered in Cambridge, Massachusetts
- Backed by leading life sciences investors
- Focused on Parkinson's disease, Alzheimer's disease, and other neurological conditions
Cross-References
- Basal Ganglia Circuit in Parkinson's Disease
- Parkinson's Disease OFF Time
- Indirect Pathway in Movement Control
- Dopamine Agonists in Parkinson's Disease
- Levodopa Therapy
- [COMT Inhibitors](/therapeutics/comt-inhibitors)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- Parkinson's Disease Motor Complications
- Dyskinesias
External Links
- [ClinicalTrials.gov - NCT06553027](https://clinicaltrials.gov/study/NCT06553027)
- [Cerevance Pipeline](https://www.cerevance.com/pipeline/)
- [Parkinson's Foundation - Motor Fluctuations](https://www.parkinson.org/)
References
Unknown, GPR6 expression in striatal medium spiny neurons. Cerevance NETSseq platform data (n.d.)
Unknown, Cerevance Pipeline: CVN424 for Parkinson's Disease (n.d.)
Unknown, CVN424 Phase 2 ASCEND Trial Results. Cerevance. Positive results reported March 2022; topline presented at AD/PD 2025 (2022)Pathway Diagram
The following diagram shows the key molecular relationships involving CVN424 Phase 3 ARISE Trial for Parkinson's Disease discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)